J&J Raises Annual Forecast After Selling Elan Stake

Photographer: Scott Eells/Bloomberg

Second-quarter net income was $3.83 billion, or $1.33 a share. Close

Second-quarter net income was $3.83 billion, or $1.33 a share.

Photographer: Scott Eells/Bloomberg

Second-quarter net income was $3.83 billion, or $1.33 a share.

Johnson & Johnson (JNJ), the world’s biggest maker of health-care products, more than doubled its earnings in the second quarter after selling its stake in Elan Corp. The company also boosted its profit forecast.

Earnings excluding one-time items for 2013 will be $5.40 to $5.47 a share, the New Brunswick, New Jersey-based company said in a statement today. Second-quarter net income was $3.83 billion, or $1.33 a share. Profit of $1.48 a share beat by 9 cents the average of 20 analyst estimates compiled by Bloomberg.

J&J sold its share of Elan in April and June for $1.26 billion, ending the relationship started with the Irish biotechnology company to develop an Alzheimer’s drug. This was the second consecutive time J&J benefited from a one-time gain, after first-quarter results were helped by reversal of a payment to the U.S. Medicaid insurance program for the poor.

“This quarter reinforces our belief that growth will continue to accelerate,” said Judson Clark, an analyst with Edward Jones & Co. in Des Peres, Missouri. “The results were distorted by the sale of biotech company Elan. As such, we are not concerned by the lack of a larger guidance bump, and view the guidance raise as a clear positive.”

Prior Forecast

In January, J&J had forecast profit of $5.35 to $5.45 a share for 2013.

Second-quarter sales rose 8.5 percent to $17.9 billion, helped by demand for the company’s newer pharmaceutical offerings including the blood thinner Xarelto and the prostate cancer medicine Zytiga. The company reported net income of $1.41 billion, or 51 cents, a year earlier, when results were hurt by acquisition costs.

J&J shares closed unchanged at $90.40 in New York trading. They have increased 32 percent in the 12 months.

The U.S. company had bought 18 percent of Elan for $1 billion in 2009.

Revenue from J&J’s pharmaceutical products grew 12 percent to $7 billion, helped by a 9.8 percent increase in sales of the rheumatoid arthritis treatment Remicade to $1.67 billion. Sales were also helped by the addition of newer products, including a 70 percent increase in sales of the prostate cancer treatment Zytiga to $395 million and a more than three-fold increase in sales of the anti-clotting drug Xarelto to $189 million.

Eight of the company’s therapies introduced since 2011 generated $4.4 billion last year, propelling J&J to the fastest growth among large drugmakers.

Sales of consumer goods and over-the-counter medicines, including Tylenol and Motrin, climbed 1.1 percent to $3.66 billion as the McNeil unit continues to return recalled products to U.S. store shelves. The medical device and diagnostic unit, the company’s biggest, saw sales rise 9.6 percent to $7.19 billion, helped by the acquisition of Synthes Inc.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at Shannon Pettypiece in New York at

To contact the editor responsible for this story: Reg Gale at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.